EGFR and non-small cell lung carcinoma: However, as most of these trials were limited to patients with the so-called “common” EGFR mutations (exon 19 deletions [Del19] and the L858R mutation in exon 21) few prospective data are available to inform treatment decisions for the estimated 7%-23% of EGFR mutation-positive NSCLC tumors that harbor uncommon EGFR mutations.15-22 To date, only 4 randomized trials of EGFR TKIs have included a small number of patients with uncommon mutations: IPASS (gefitinib4), NEJ002 (gefitinib5), and LUX-Lung 3 and 6 (afatinib7,8).